Related Experiment Video
Updated: May 10, 2026
06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Alpha1-antitrypsin deficiency: a clinical-genetic overview
Raja T Abboud1, Tanya N Nelson, Benjamin Jung
1Department of Medicine, Respiratory Division, University of British Columbia, Vancouver, BC, Canada.
The Application of Clinical Genetics
|June 19, 2013
Summary
Severe alpha1-antitrypsin deficiency (AATD) causes emphysema in smokers. Augmentation therapy showed a trend toward slower lung damage progression in clinical trials.
Area of Science:
- Genetics and Respiratory Medicine
Background:
- Alpha1-antitrypsin deficiency (AATD) is an inherited condition causing emphysema, particularly in smokers, due to neutrophil elastase activity.
- The SERPINA1 gene determines alpha1-antitrypsin (AAT) levels, with M, S, and Z alleles impacting plasma concentrations and disease risk.
- Severe AAT deficiency (ZZ genotype) can lead to liver disease, including neonatal hepatitis and adult liver conditions, due to abnormal AAT retention.
Purpose of the Study:
- To evaluate the efficacy of alpha1-antitrypsin (AAT) augmentation therapy in slowing emphysema progression in patients with severe AATD.
- To review diagnostic methods and recommended testing strategies for identifying AATD.
Main Methods:
- Analysis of integrated data from two randomized controlled trials of intravenous AAT augmentation therapy.
- Review of diagnostic techniques including immunologic measurement, isoelectric focusing, DNA analysis, and gene sequencing for AAT.
- Assessment of clinical guidelines for AATD testing in at-risk populations.
Main Results:
- Integrated analysis of two trials indicated significantly slower progression of emphysema in patients receiving AAT augmentation therapy.
- AAT augmentation therapy demonstrated a trend toward slower emphysema progression by chest computerized tomography.
- AATD is frequently underdiagnosed, highlighting the need for increased testing in patients with airflow obstruction and liver disease.
Conclusions:
- AAT augmentation therapy may slow emphysema progression in individuals with severe AATD.
- Timely diagnosis of AATD through recommended testing is crucial for early intervention and management.
- Genetic testing for AATD is recommended for patients with early-onset emphysema, family history, or unexplained liver disease.
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:25Chronic Pancreatitis I: Introduction
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
01:24Chronic Pancreatitis I: Introduction
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.